Intelligent Bio Solutions clears cybersecurity, software review items ahead of FDA 510(k) filing in H2 2026

Intelligent Bio Solutions has cleared cybersecurity and software documentation requirements for its planned FDA 510(k) filing, scheduled for the second half of 2026. The submission targets initial clearance for codeine detection. The company achieved 100% remediation of medium-risk penetration test issues and reduced low-risk items from 11 to 2.

Intelligent Bio Solutions cleared cybersecurity and software documentation items tied to its planned FDA 510(k) filing. * Submission remains slated for H2 2026, targeting initial clearance for codeine detection. * Penetration-test remediation reached 100% for medium-risk issues; low-risk items cut to 2 from 11. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intelligent Bio Solutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230830PRIMZONEFULLFEED9766877) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)